Physician profile
Michael Macmillan
NPI 1902834666
$105,386.27
in general payments reported to CMS, 2019-2025
5 companies · $16K in 2025
The $16K reported for 2025 was more than what 90% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,245 · 2020: $2,445 · 2021: $2,400 · 2022: $17K · 2023: $14K · 2024: $45K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $59K · Travel and Lodging: $7,806 · Royalty Or License: $6,327 · Food and Beverage: $1,905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $58,543.47 |
| Travel and Lodging | $7,806.26 |
| Royalty Or License | $6,326.81 |
| Food and Beverage | $1,904.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novapproach Spine, LLC | $90,462.44 | 2022-2025 | Onelif |
| Spineology INC. | $13,500.00 | 2019-2022 | |
| Zimmer Biomet Holdings, INC. | $1,344.65 | 2019 | |
| Seaspine Orthopedics Corporation | $44.73 | 2020 | |
| Medtronic, INC. | $34.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$4,309,277.25 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Macmillan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.